Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2014 08:00 ET | Source: Vital Therapies, Inc.

Vital Therapies Announces Management Addition; Enrollment in VTI-208 Phase 3 Trial Now 75 Percent Complete

SAN DIEGO, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is...
August 06, 2014 16:34 ET | Source: Vital Therapies, Inc.

Vital Therapies Announces Second Quarter 2014 Financial Results and Provides Update on Operations and Upcoming Conference Presentations

SAN DIEGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
July 28, 2014 16:15 ET | Source: Vital Therapies, Inc.

Vital Therapies Announces Poster Presentation at the 2014 World Transplant Congress

SAN DIEGO, July 28, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure,...
July 09, 2014 05:30 ET | Source: Vital Therapies, Inc.

Vital Therapies Reports on Clinical Trial Progress and EU Regulatory Advice

SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is...